openPR Logo
Press release

Investigation announced for Investors who hold shares of Humacyte, Inc. (NASDAQ: HUMA)

An investigation on behalf of current long term investors in Humacyte, Inc. (NASDAQ: HUMA) shares.

An investigation on behalf of current long term investors in Humacyte, Inc. (NASDAQ: HUMA) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Humacyte, Inc.

Investors who are current long term investors in Humacyte, Inc. (NASDAQ: HUMA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: HUMA stocks follows a lawsuit filed against Humacyte, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: HUMA stocks, concerns whether certain Humacyte directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Middle District of North Carolina the plaintiff alleges that the Defendants failed to disclose to investors that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing, that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies, that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Humacyte, Inc. (NASDAQ: HUMA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors who hold shares of Humacyte, Inc. (NASDAQ: HUMA) here

News-ID: 3963928 • Views:

More Releases from Shareholders Foundation, Inc.

Investigation announced for Long-Term Investors in shares of Organon & Co. (NYSE: OGN) concerning potential Wrongdoing
Investigation announced for Long-Term Investors in shares of Organon & Co. (NYSE …
An investigation was announced for current long-term investors in shares of Organon & Co. (NYSE: OGN) concerning potential breaches of fiduciary duties by certain directors of Organon & Co. Investors who are current long term investors in Organon & Co. (NYSE: OGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors
Lawsuit filed for Investors who lost money with shares of Charter Communications, Inc. (NASDAQ: CHTR)
Lawsuit filed for Investors who lost money with shares of Charter Communications …
An investor, who purchased shares of Charter Communications, Inc. (NASDAQ: CHTR), filed a lawsuit over alleged violations of Federal Securities Laws by Charter Communications, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Charter Communications, Inc. (NASDAQ: CHTR) have certain options and for certain investors are short and strict deadlines running. Deadline: October 14, 2025. NASDAQ: CHTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investigation announced for Investors in Vestis Corporation (NYSE: VSTS) over potential Wrongdoing
Investigation announced for Investors in Vestis Corporation (NYSE: VSTS) over po …
An investigation was announced for current long-term investors in shares of Vestis Corporation (NYSE: VSTS) concerning potential breaches of fiduciary duties by certain directors of Vestis Corporation. Investors who are current long term investors in Vestis Corporation (NYSE: VSTS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: VSTS
iRobot Corporation (NASDAQ: IRBT) Investor Alert: Deadline in Lawsuit on September 5, 2025
iRobot Corporation (NASDAQ: IRBT) Investor Alert: Deadline in Lawsuit on Septemb …
A deadline is coming up on September 5, 2025 in the lawsuit filed for certain investors of iRobot Corporation (NASDAQ: IRBT) over alleged securities laws violations by iRobot Corporation. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and there are strict and short deadlines running. Deadline: September 5, 2025. iRobot Corporation (NASDAQ: IRBT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According

All 5 Releases


More Releases for Humacyte

Peripheral Artery Disease Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clini …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral Artery Disease pipeline constitutes 20+ key companies continuously working towards developing 22+ Peripheral Artery Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Peripheral Artery Disease Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral Artery Disease Market. The
Peripheral Artery Disease MARKET TO WITNESS UPSURGE IN GROWTH DURING THE FORECAS …
According to DelveInsight's analysis, the Peripheral Artery Disease (PAD) market is projected to experience significant growth in the foreseeable future. This trajectory is attributed to the increasing prevalence of PAD across the 7 major markets (7MM), ongoing Research and Development (R&D) endeavors, the active involvement of leading pharmaceutical and biotechnology companies in this therapeutic area, and the anticipated introduction of emerging therapies. In 2022, the market size of Peripheral Artery Disease
Peripheral Artery Disease Market to Witness Upsurge in Growth During the Forecas …
DelveInsight's "Peripheral Artery Disease Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Peripheral Artery Disease, historical and forecasted epidemiology as well as the Peripheral Artery Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. According to DelveInsight's analysis, the Peripheral Artery Disease (PAD) market is projected to experience significant growth in the foreseeable future. This
Global Vascular Bioprostheses Market |COVID-19 Analysis, Historical Data and Dri …
Vascular bioprostheses replace many severely narrowed or blocked blood vessels and are suitable for vascular bypass surgery throughout the body. Artificial blood vessels of large and medium caliber have been used in clinical practice with satisfactory results. The Vascular Bioprostheses report from Report Consultant is rigorous research. Experts with proven expertise in senior research positions conduct in-depth analysis of the subject, opening an unrivaled repository of domain knowledge and broad research
Vascular Grafts Market Report- Growth, Trends and Forecast to 2023 | Humacyte In …
The Vascular Grafts Market research report provides qualitative and quantitative parameters of the Vascular Grafts Market. Vascular Grafts Market provides a detailed analysis by highlighting the driving and restraining factors of the market. Vascular Grafts Market research study offers the analysis of the key vendors by considering their contribution to the overall market. Vascular Grafts Market also provides in-depth insights about vendors’ performance in terms of revenue generation and clients’
Artificial Blood Vessels Market Top Key Vendors- Terumo Medical Corporation, Art …
Zion Market Research published a new 110+ pages industry research “Global Artificial Blood Vessels Market Set for Rapid Growth, to reach Value around USD 3,158.8 Million by 2025” is exhaustively researched and analyzed in the report to help market players to improve their business tactics and ensure long-term success. The authors of the report have used easy-to-understand language and uncomplicated statistical images but provided thorough information and detailed data on